World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website https://www.wjon.org

Original Article

Volume 14, Number 6, December 2023, pages 488-498

Prevalence and Prognosis of Secondary Genetic Aberrations Among Patients With Core Binding Factor Acute Myeloid Leukemia: A Mitelman Database Analysis

Figure 1. Plot created with BioCircos package in R showing with sky-blue lines secondary genetic mutations and gene fusions found in core binding factor acute myeloid leukemia (CBF-AML) cases in Mitelman Database. Chromosomes are individually colored and arranged clockwise from chromosome 1 to Y. We showed only mutations with a frequency greater than 1, and there were no rearrangements involving the Y chromosome. NRAS: neuroblastoma RAS viral gene mutation; ASXL2: ASXL transcriptional regulator 2 gene mutation; RUNX1-RUNX1T1: RUNX1-RUNX1 partner transcriptional co-repressor 1 genes fusion; BCR-ABL1: BCR-ABL1 fusion gene mutation; PTEN: phosphatase and tensin homolog gene mutation; CCND1: cyclin D1 gene mutation; CCND2: cyclin D2 gene mutation; CBL: casitas B-lineage lymphoma gene mutation; KRAS: Kirsten rat sarcoma virus gene mutation; FLT3: FMS-like tyrosine kinase 3 gene mutation; IDH2R140: isocitrate dehydrogenase 2 R140 gene mutation; CBFB-MYH11: core binding factor beta subunit-myosin heavy chain 11 genes fusion; PML-RARa: promyelocytic leukemia/retinoic acid receptor alpha gene mutation; ASXL1: ASXL transcriptional regulator 1 gene mutation; ZRSR2: zinc finger, RNA-binding motif and serine/arginine rich 2 gene mutation; BCORL1: BCORL1 gene mutation; BRCC3: BRCA1/BRCA2-containing complex 3 gene mutation.

Figure 2. (a) Kaplan Meier curves for core binding factor acute myeloid leukemia (CBF-AML) groups showed no significant difference between groups. Five-year survival data of CBF-AML cases with secondary genetic findings: (b) Numerical chromosome abnormalities (5-year OS: 74.8%, 95% CI: 64.8 - 86.2, versus 60.4%, 95% CI: 50.1 - 72.9); (c) Structural chromosome rearrangements (5-year OS: 61.9%, 95% CI: 45.1 - 84.9, versus 67.5%, 95% CI: 59.2 - 77.0); (d) Secondary genetic mutations (5-year OS: 64.5%, 95% CI: 54.6 - 76.1, versus 68.9%, 95% CI: 57.5 - 82.4). CI: confidence interval; OS: overall survival.

Figure 3. Five-year survival data of CBF-AML cases with specific secondary genetic aberration: (a) 7q deletion “del(7)” (5-year OS in total sample: 27.8%, 95% CI: 5.39 - 100, versus 67.7%, 95% CI: 60.1 - 76.2); (b) Trisomy 22 “+22” (5-year OS in total sample: 38.6%, 95% CI: 13.5 - 100, versus 67.9%, 95% CI: 60.2 - 76.5); (c) Loss of chromosome X “-X” (5-year OS in t(8;21) group: 72.7%, 95% CI: 50.6 - 100, versus 73.6%, 95% CI: 64.9 - 83.5); (d) Loss of chromosome Y “-Y” (5-year OS in t(8;21) group: 80.4%, 95% CI: 68.2 - 94.9, versus 69.9%, 95% CI: 59.6 - 82.0); (e) KIT mutation (5-year OS in total sample: 63.5%, 95% CI: 49.2 - 81.8, versus 67.4%, 95% CI: 58.7 - 77.4); (f) NRAS mutation (5-year OS in t(8;21) group: 25.0%, 95% CI: 4.58 - 100, versus 75.4%, 95% CI: 67.1 - 84.7). -Y: loss of chromosome Y; KIT: receptor tyrosine kinase gene KIT mutation; NRAS: neuroblastoma RAS viral gene mutation. CI: confidence interval; OS: overall survival.

**Table 1.** Characteristics of 193 CBF-AML Cases From Mitelman Database Between 2010 and 2021
Variable	Overall (n = 193), n (%)	inv(16) (n = 76), n (%)	t(8;21) (n = 117), n (%)	P value
^aMedian (IQR). ^bPearson’s Chi-squared test. ^cWilcoxon rank sum test. ^dFisher’s exact test. del(7): deletion of chromosome 7; del(9): deletion of chromosome 9; t(9;22): chromosomal translocation t(9;22); +8: trisomy 8; +22: trisomy 22; -X: loss of chromosome X; -Y: loss of chromosome Y; BCR-ABL1: BCR-ABL1 fusion gene mutation; BRCC3: BRCA1/BRCA2-containing complex 3 gene mutation; NRAS: neuroblastoma RAS viral gene mutation; KRAS: Kirsten rat sarcoma virus gene mutation; KIT: receptor tyrosine kinase gene KIT mutation; CCND1: cyclin D1 gene mutation; CCND2: cyclin D2 gene mutation; ASXL1: ASXL transcriptional regulator 1 gene mutation; ASXL2: ASXL transcriptional regulator 2 gene mutation; FLT3: FMS-like tyrosine kinase 3 gene mutation; CBF-AML: core binding factor acute myeloid leukemia; AML: acute myeloid leukemia.
Sex				0.404^b
Female	73 (37.8)	26 (34.2)	47 (40.2)
Male	120 (62.2)	50 (65.8)	70 (59.8)
Age at diagnosis (median)	43.0 (25.0, 53.0)^a	40.5 (28.8, 53.2)^a	45.0 (23.0, 52.0)^a	0.748^c
Age group (years)				0.230^b
Pediatric (< 18)	31 (16.1)	8 (10.5)	23 (19.7)
Adult (18 - 64)	142 (73.6)	59 (77.6)	83 (70.9)
Elderly (≥ 65)	20 (10.4)	9 (11.8)	11 (9.4)
FAB classification				< 0.001^d
AML without maturation (M1)	9 (4.7)	2 (2.6)	7 (6.0)
AML with maturation (M2)	33 (17.1)	3 (3.9)	30 (25.6)
Acute promyelocytic leukemia (M3)	1 (0.5)	0 (0.0)	1 (0.9)
Acute myelomonocytic leukemia (M4)	20 (10.4)	18 (23.7)	2 (1.7)
Acute monoblastic or monocytic leukemia (M5)	2 (1.0)	1 (1.3)	1 (0.9)
AML not otherwise specified (NOS)	128 (66.3)	52 (68.4)	76 (65.0)
Chromosome number				< 0.001^b
< 46	54 (28.0)	0 (0.0)	54 (46.2)
46	112 (58.0)	55 (72.4)	57 (48.7)
> 46	27 (14.0)	21 (27.6)	6 (5.1)
Structural chromosome rearrangements	50 (25.9)	22 (28.9)	28 (23.9)	0.437^b
del(7)	6 (3.1)	4 (5.3)	2 (1.7)	0.214^d
del(9)	12 (6.2)	0 (0.0)	12 (10.3)	0.004^d
t(9;22)	9 (4.7)	8 (10.5)	1 (0.9)	0.003^d
Numerical chromosome abnormalities	79 (40.9)	21 (27.6)	58 (49.6)	0.002^b
+8	12 (6.2)	10 (13.2)	2 (1.7)	0.002^d
+22	10 (5.2)	10 (13.2)	0 (0.0)	< 0.001^d
-X	11 (5.7)	0 (0.0)	11 (9.4)	0.004^d
-Y	42 (21.8)	0 (0.0)	42 (35.9)	< 0.001^b
Secondary genetic mutations	106 (54.9)	40 (52.6)	66 (56.4)	0.606^b
BCR-ABL1	12 (6.2)	12 (15.8)	0 (0.0)	< 0.001^d
BRCC3	8 (4.1)	0 (0.0)	8 (6.8)	0.023^d
NRAS	8 (4.1)	4 (5.3)	4 (3.4)	0.714^d
KRAS	2 (1.0)	2 (2.6)	0 (0.0)	0.154^d
KIT	41 (21.2)	17 (22.4)	24 (20.5)	0.758^b
CCND1	3 (1.6)	0 (0.0)	3 (2.6)	0.280^d
CCND2	10 (5.2)	0 (0.0)	10 (8.5)	0.007^d
ASXL1	11 (5.7)	1 (1.3)	10 (8.5)	0.053^d
ASXL2	11 (5.7)	0 (0.0)	11 (9.4)	0.004^d
FLT3	11 (5.7)	5 (6.6)	6 (5.1)	0.755^d
Relapse	134 (69.4)	61 (80.3)	73 (62.4)	0.008^b
Status				0.266^b
Alive	143 (74.1)	53 (69.7)	90 (76.9)
Dead	50 (25.9)	23 (30.3)	27 (23.1)
Overall survival (months)	28.8 (12.0, 60.0)^a	23.2 (10.0, 50.6)^a	36.0 (16.8, 60.0)^a	0.009^c

Table 1. Characteristics of 193 CBF-AML Cases From Mitelman Database Between 2010 and 2021

Variable

Overall (n = 193), n (%)

inv(16) (n = 76), n (%)

t(8;21) (n = 117), n (%)

P value

^aMedian (IQR). ^bPearson’s Chi-squared test. ^cWilcoxon rank sum test. ^dFisher’s exact test. del(7): deletion of chromosome 7; del(9): deletion of chromosome 9; t(9;22): chromosomal translocation t(9;22); +8: trisomy 8; +22: trisomy 22; -X: loss of chromosome X; -Y: loss of chromosome Y; BCR-ABL1: BCR-ABL1 fusion gene mutation; BRCC3: BRCA1/BRCA2-containing complex 3 gene mutation; NRAS: neuroblastoma RAS viral gene mutation; KRAS: Kirsten rat sarcoma virus gene mutation; KIT: receptor tyrosine kinase gene KIT mutation; CCND1: cyclin D1 gene mutation; CCND2: cyclin D2 gene mutation; ASXL1: ASXL transcriptional regulator 1 gene mutation; ASXL2: ASXL transcriptional regulator 2 gene mutation; FLT3: FMS-like tyrosine kinase 3 gene mutation; CBF-AML: core binding factor acute myeloid leukemia; AML: acute myeloid leukemia.

Sex

0.404^b

Female

73 (37.8)

26 (34.2)

47 (40.2)

Male

120 (62.2)

50 (65.8)

70 (59.8)

Age at diagnosis (median)

43.0 (25.0, 53.0)^a

40.5 (28.8, 53.2)^a

45.0 (23.0, 52.0)^a

0.748^c

Age group (years)

0.230^b

Pediatric (< 18)

31 (16.1)

8 (10.5)

23 (19.7)

Adult (18 - 64)

142 (73.6)

59 (77.6)

83 (70.9)

Elderly (≥ 65)

20 (10.4)

9 (11.8)

11 (9.4)

FAB classification

< 0.001^d

AML without maturation (M1)

9 (4.7)

2 (2.6)

7 (6.0)

AML with maturation (M2)

33 (17.1)

3 (3.9)

30 (25.6)

Acute promyelocytic leukemia (M3)

1 (0.5)

0 (0.0)

1 (0.9)

Acute myelomonocytic leukemia (M4)

20 (10.4)

18 (23.7)

2 (1.7)

Acute monoblastic or monocytic leukemia (M5)

2 (1.0)

1 (1.3)

1 (0.9)

AML not otherwise specified (NOS)

128 (66.3)

52 (68.4)

76 (65.0)

Chromosome number

< 0.001^b

< 46

54 (28.0)

0 (0.0)

54 (46.2)

112 (58.0)

55 (72.4)

57 (48.7)

> 46

27 (14.0)

21 (27.6)

6 (5.1)

Structural chromosome rearrangements

50 (25.9)

22 (28.9)

28 (23.9)

0.437^b

del(7)

6 (3.1)

4 (5.3)

2 (1.7)

0.214^d

del(9)

12 (6.2)

0 (0.0)

12 (10.3)

0.004^d

t(9;22)

9 (4.7)

8 (10.5)

1 (0.9)

0.003^d

Numerical chromosome abnormalities

79 (40.9)

21 (27.6)

58 (49.6)

0.002^b

12 (6.2)

10 (13.2)

2 (1.7)

0.002^d

+22

10 (5.2)

10 (13.2)

0 (0.0)

< 0.001^d

-X

11 (5.7)

0 (0.0)

11 (9.4)

0.004^d

-Y

42 (21.8)

0 (0.0)

42 (35.9)

< 0.001^b

Secondary genetic mutations

106 (54.9)

40 (52.6)

66 (56.4)

0.606^b

BCR-ABL1

12 (6.2)

12 (15.8)

0 (0.0)

< 0.001^d

BRCC3

8 (4.1)

0 (0.0)

8 (6.8)

0.023^d

NRAS

8 (4.1)

4 (5.3)

4 (3.4)

0.714^d

KRAS

2 (1.0)

2 (2.6)

0 (0.0)

0.154^d

KIT

41 (21.2)

17 (22.4)

24 (20.5)

0.758^b

CCND1

3 (1.6)

0 (0.0)

3 (2.6)

0.280^d

CCND2

10 (5.2)

0 (0.0)

10 (8.5)

0.007^d

ASXL1

11 (5.7)

1 (1.3)

10 (8.5)

0.053^d

ASXL2

11 (5.7)

0 (0.0)

11 (9.4)

0.004^d

FLT3

11 (5.7)

5 (6.6)

6 (5.1)

0.755^d

Relapse

134 (69.4)

61 (80.3)

73 (62.4)

0.008^b

Status

0.266^b

Alive

143 (74.1)

53 (69.7)

90 (76.9)

Dead

50 (25.9)

23 (30.3)

27 (23.1)

Overall survival (months)

28.8 (12.0, 60.0)^a

23.2 (10.0, 50.6)^a

36.0 (16.8, 60.0)^a

0.009^c

**Table 2.** Differences in the Characteristics of 193 CBF-AML Cases With Chromosome Aberrations
Variable	Overall (n = 193), n (%)	del(7) (n = 6), n (%)	del(9) (n = 12), n (%)	t(9;22) (n = 9), n (%)	+8 (n = 12), n (%)	+22 (n = 10), n (%)	-X (n = 11), n (%)	-Y (n = 42), n (%)
^aMedian (IQR). ^bFisher’s exact test. ^cWilcoxon rank sum test. ^dPearson’s Chi-squared test. del(7): deletion of chromosome 7; del(9): deletion of chromosome 9; t(9;22): chromosomal translocation t(9;22); +8: trisomy 8; +22: trisomy 22; -X: loss of chromosome X; -Y: loss of chromosome Y; CBF-AML: core binding factor acute myeloid leukemia.
CBF-AML group
inv(16)	76 (39.4)	4 (66.7)	0 (0.0)	8 (88.9)	10 (83.3)	10 (100.0)	0 (0.0)	0 (0.0)
t(8;21)	117 (60.6)	2 (33.3)	12 (100.0)	1 (11.1)	2 (16.7)	0 (0.0)	11 (100.0)	42 (100.0)
P value		0.214^b	0.004^b	0.003^b	0.002^b	< 0.001^b	0.004^b	< 0.001^d
Sex
Female	73 (37.8)	2 (33.3)	4 (33.3)	3 (33.3)	5 (41.7)	4 (40.0)	11 (100.0)	0 (0.0)
Male	120 (62.2)	4 (66.7)	8 (66.7)	6 (66.7)	7 (58.3)	6 (60.0)	0 (0.0)	42 (100.0)
P value		> 0.999^b	> 0.999^b	> 0.999^b	> 0.999^b	> 0.999^b	< 0.001^b	< 0.001^d
Age at diagnosis (median)	43.0 (25.0, 53.0)^a	43.5 (28.8, 50.0)^a	29.0 (19.0, 47.2)^a	38.0 (31.0, 49.0)^a	39.0 (29.8, 49.5)^a	43.5 (18.5, 47.8)^a	50.3 (37.0, 56.0)^a	42.5 (25.0, 50.3)^a
P value		0.941^c	0.298^c	0.830^c	0.697^c	0.532^c	0.307^c	0.277^c
Age group (years)
Pediatric (< 18)	31 (16.1)	1 (16.7)	2 (16.7)	0 (0.0)	2 (16.7)	2 (20.0)	2 (18.2)	9 (21.4)
Adult (18 - 64)	142 (73.6)	5 (83.3)	9 (75.0)	8 (88.9)	9 (75.0)	7 (70.0)	8 (72.7)	31 (73.8)
Elderly (≥ 65)	20 (10.4)	0 (0.0)	1 (8.3)	1 (11.1)	1 (8.3)	1 (10.0)	1 (9.1)	2 (4.8)
P value		> 0.999^b	> 0.999^b	0.510^b	> 0.999^b	0.867^b	> 0.999^b	0.298^b
Chromosome number
< 46	54 (28.0)	0 (0.0)	6 (50.0)	1 (11.1)	0 (0.0)	0 (0.0)	10 (90.9)	41 (97.6)
46	112 (58.0)	4 (66.7)	5 (41.7)	5 (55.6)	1 (8.3)	0 (0.0)	1 (9.1)	0 (0.0)
> 46	27 (14.0)	2 (33.3)	1 (8.3)	3 (33.3)	11 (91.7)	10 (100.0)	0 (0.0)	1 (2.4)
P value		0.137^b	0.246^b	0.191^b	< 0.001^b	< 0.001^b	< 0.001^b	< 0.001^d
Relapse	134 (69.4)	6 (100.0)	10 (83.3)	6 (66.7)	11 (91.7)	9 (90.0)	7 (63.6)	29 (69.0)
P value		0.180^b	0.351^b	> 0.999^b	0.110^b	0.288^b	0.739^b	0.952^d
Status
Alive	143 (74.1)	3 (50.0)	9 (75.0)	7 (77.8)	7 (58.3)	6 (60.0)	8 (72.7)	35 (83.3)
Dead	50 (25.9)	3 (50.0)	3 (25.0)	2 (22.2)	5 (41.7)	4 (40.0)	3 (27.3)	7 (16.7)
P value		0.181^b	> 0.999^b	> 0.999^b	0.304^b	0.287^b	> 0.999^b	0.122^d
Overall survival (months)	28.8 (12.0, 60.0)^a	10.5 (6.6, 25.1)^a	33.0 (26.2, 48.0)^a	22.0 (10.0, 65.0)^a	23.1 (6.2, 66.5)^a	16.0 (1.7, 28.0)^a	30.0 (26.9, 54.0)^a	48.0 (26.9, 93.5)^a
P value		0.050^c	0.716^c	0.649^c	0.406^c	0.011^c	0.506^c	0.004^c

Table 2. Differences in the Characteristics of 193 CBF-AML Cases With Chromosome Aberrations

Variable

Overall (n = 193), n (%)

del(7) (n = 6), n (%)

del(9) (n = 12), n (%)

t(9;22) (n = 9), n (%)

+8 (n = 12), n (%)

+22 (n = 10), n (%)

-X (n = 11), n (%)

-Y (n = 42), n (%)

^aMedian (IQR). ^bFisher’s exact test. ^cWilcoxon rank sum test. ^dPearson’s Chi-squared test. del(7): deletion of chromosome 7; del(9): deletion of chromosome 9; t(9;22): chromosomal translocation t(9;22); +8: trisomy 8; +22: trisomy 22; -X: loss of chromosome X; -Y: loss of chromosome Y; CBF-AML: core binding factor acute myeloid leukemia.

CBF-AML group

inv(16)

76 (39.4)

4 (66.7)

0 (0.0)

8 (88.9)

10 (83.3)

10 (100.0)

0 (0.0)

t(8;21)

117 (60.6)

2 (33.3)

12 (100.0)

1 (11.1)

2 (16.7)

0 (0.0)

11 (100.0)

42 (100.0)

P value

0.214^b

0.004^b

0.003^b

0.002^b

< 0.001^b

0.004^b

< 0.001^d

Sex

Female

73 (37.8)

2 (33.3)

4 (33.3)

3 (33.3)

5 (41.7)

4 (40.0)

11 (100.0)

0 (0.0)

Male

120 (62.2)

4 (66.7)

8 (66.7)

6 (66.7)

7 (58.3)

6 (60.0)

0 (0.0)

42 (100.0)

P value

> 0.999^b

< 0.001^b

< 0.001^d

Age at diagnosis (median)

43.0 (25.0, 53.0)^a

43.5 (28.8, 50.0)^a

29.0 (19.0, 47.2)^a

38.0 (31.0, 49.0)^a

39.0 (29.8, 49.5)^a

43.5 (18.5, 47.8)^a

50.3 (37.0, 56.0)^a

42.5 (25.0, 50.3)^a

P value

0.941^c

0.298^c

0.830^c

0.697^c

0.532^c

0.307^c

0.277^c

Age group (years)

Pediatric (< 18)

31 (16.1)

1 (16.7)

2 (16.7)

0 (0.0)

2 (16.7)

2 (20.0)

2 (18.2)

9 (21.4)

Adult (18 - 64)

142 (73.6)

5 (83.3)

9 (75.0)

8 (88.9)

9 (75.0)

7 (70.0)

8 (72.7)

31 (73.8)

Elderly (≥ 65)

20 (10.4)

0 (0.0)

1 (8.3)

1 (11.1)

1 (8.3)

1 (10.0)

1 (9.1)

2 (4.8)

P value

> 0.999^b

0.510^b

> 0.999^b

0.867^b

> 0.999^b

0.298^b

Chromosome number

< 46

54 (28.0)

0 (0.0)

6 (50.0)

1 (11.1)

0 (0.0)

10 (90.9)

41 (97.6)

112 (58.0)

4 (66.7)

5 (41.7)

5 (55.6)

1 (8.3)

0 (0.0)

1 (9.1)

0 (0.0)

> 46

27 (14.0)

2 (33.3)

1 (8.3)

3 (33.3)

11 (91.7)

10 (100.0)

0 (0.0)

1 (2.4)

P value

0.137^b

0.246^b

0.191^b

< 0.001^b

< 0.001^d

Relapse

134 (69.4)

6 (100.0)

10 (83.3)

6 (66.7)

11 (91.7)

9 (90.0)

7 (63.6)

29 (69.0)

P value

0.180^b

0.351^b

> 0.999^b

0.110^b

0.288^b

0.739^b

0.952^d

Status

Alive

143 (74.1)

3 (50.0)

9 (75.0)

7 (77.8)

7 (58.3)

6 (60.0)

8 (72.7)

35 (83.3)

Dead

50 (25.9)

3 (50.0)

3 (25.0)

2 (22.2)

5 (41.7)

4 (40.0)

3 (27.3)

7 (16.7)

P value

0.181^b

> 0.999^b

0.304^b

0.287^b

> 0.999^b

0.122^d

Overall survival (months)

28.8 (12.0, 60.0)^a

10.5 (6.6, 25.1)^a

33.0 (26.2, 48.0)^a

22.0 (10.0, 65.0)^a

23.1 (6.2, 66.5)^a

16.0 (1.7, 28.0)^a

30.0 (26.9, 54.0)^a

48.0 (26.9, 93.5)^a

P value

0.050^c

0.716^c

0.649^c

0.406^c

0.011^c

0.506^c

0.004^c

**Table 3.** Univariate and Multivariate Cox Regression of Survival Outcomes in Patients With CBF-AML
Variable	Univariate Cox regression	Multivariate Cox regression^a
^aAll multivariate analyses were adjusted for sex, age group and relapse. del(7): deletion of chromosome 7; +22: trisomy 22; -X: loss of chromosome X; -Y: loss of chromosome Y; NRAS: neuroblastoma RAS viral gene mutation; KIT: receptor tyrosine kinase gene KIT mutation; CBF-AML: core binding factor acute myeloid leukemia; HR: hazard ratio; 95% CI: 95% confidence interval.
Structural chromosome rearrangements	0.95	0.50 - 1.80	0.884	0.96	0.50 - 1.90	0.915
del(7)	3.40	1.00 - 11.00	0.041	4.20	1.27 - 14.20	0.019
Numerical chromosome abnormalities	0.64	0.36 - 1.20	0.139	0.79	0.42 - 1.50	0.456
+22	2.8	1.00 - 7.90	0.049	3.60	1.26 - 10.50	0.017
-X	1.00	0.31 - 3.50	0.946	0.74	0.21 - 2.60	0.642
-Y	0.54	0.23 - 1.30	0.16	1.10	0.33 - 3.80	0.856
Secondary genetic mutations	1.20	0.67 - 2.10	0.568	1.10	0.64 - 2.00	0.654
NRAS	4.00	1.20 - 13.00	0.025	3.00	0.86 - 10.20	0.084
KIT	1.20	0.65 - 2.30	0.543	1.10	0.57 - 2.10	0.807

Table 3. Univariate and Multivariate Cox Regression of Survival Outcomes in Patients With CBF-AML

Variable

Univariate Cox regression

Multivariate Cox regression^a

95% CI

P value

95% CI

P value

^aAll multivariate analyses were adjusted for sex, age group and relapse. del(7): deletion of chromosome 7; +22: trisomy 22; -X: loss of chromosome X; -Y: loss of chromosome Y; NRAS: neuroblastoma RAS viral gene mutation; KIT: receptor tyrosine kinase gene KIT mutation; CBF-AML: core binding factor acute myeloid leukemia; HR: hazard ratio; 95% CI: 95% confidence interval.

Structural chromosome rearrangements

0.95

0.50 - 1.80

0.884

0.96

0.50 - 1.90

0.915

del(7)

3.40

1.00 - 11.00

0.041

4.20

1.27 - 14.20

0.019

Numerical chromosome abnormalities

0.64

0.36 - 1.20

0.139

0.79

0.42 - 1.50

0.456

+22

2.8

1.00 - 7.90

0.049

3.60

1.26 - 10.50

0.017

-X

1.00

0.31 - 3.50

0.946

0.74

0.21 - 2.60

0.642

-Y

0.54

0.23 - 1.30

0.16

1.10

0.33 - 3.80

0.856

Secondary genetic mutations

1.20

0.67 - 2.10

0.568

1.10

0.64 - 2.00

0.654

NRAS

4.00

1.20 - 13.00

0.025

3.00

0.86 - 10.20

0.084

KIT

1.20

0.65 - 2.30

0.543

1.10

0.57 - 2.10

0.807